Capricor Therapeutics, Inc.

NasdaqCM:CAPR Stock Report

Market Cap: US$913.8m

Capricor Therapeutics Past Earnings Performance

Past criteria checks 0/6

Capricor Therapeutics's earnings have been declining at an average annual rate of -23.8%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 78.4% per year.

Key information

-23.8%

Earnings growth rate

21.9%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate78.4%
Return on equity-243.0%
Net Margin-102.9%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Sep 18
Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Investors Don't See Light At End Of Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Tunnel

Jul 30
Investors Don't See Light At End Of Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Tunnel

Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up

May 08
Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up

Benign Growth For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Underpins Stock's 26% Plummet

Apr 19
Benign Growth For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Underpins Stock's 26% Plummet

We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate

Apr 16
We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate

Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip In Price Shows Sentiment Is Matching Revenues

Feb 03
Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip In Price Shows Sentiment Is Matching Revenues

Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth?

Dec 13
Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth?

Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation

Aug 13
Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation

A Look At The Fair Value Of Capricor Therapeutics, Inc. (NASDAQ:CAPR)

Nov 03
A Look At The Fair Value Of Capricor Therapeutics, Inc. (NASDAQ:CAPR)

Capricor Therapeutics GAAP EPS of -$0.29 misses by $0.03

Aug 10

Companies Like Capricor Therapeutics (NASDAQ:CAPR) Are In A Position To Invest In Growth

Feb 01
Companies Like Capricor Therapeutics (NASDAQ:CAPR) Are In A Position To Invest In Growth

Revenue & Expenses Breakdown

How Capricor Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:CAPR Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2427-28146
31 Mar 2427-24130
31 Dec 2325-22130
30 Sep 2314-291216
30 Jun 239-291216
31 Mar 236-29110
31 Dec 223-29100
30 Sep 222-27100
30 Jun 220-2590
31 Mar 220-2380
31 Dec 210-2080
30 Sep 210-1870
30 Jun 210-1860
31 Mar 210-1760
31 Dec 200-1460
30 Sep 200-1150
30 Jun 201-950
31 Mar 201-740
31 Dec 191-840
30 Sep 191-940
30 Jun 192-1240
31 Mar 192-1450
31 Dec 182-1550
30 Sep 181050
30 Jun 182250
31 Mar 182250
31 Dec 173250
30 Sep 173-1450
30 Jun 174-1750
31 Mar 174-1850
31 Dec 164-1950
30 Sep 164-1850
30 Jun 165-1550
31 Mar 165-1440
31 Dec 156-1340
30 Sep 156-1140
30 Jun 156-1040
31 Mar 156-840
31 Dec 145-630
30 Sep 143-930
30 Jun 142-930
31 Mar 141-930
31 Dec 131-920

Quality Earnings: CAPR is currently unprofitable.

Growing Profit Margin: CAPR is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CAPR is unprofitable, and losses have increased over the past 5 years at a rate of 23.8% per year.

Accelerating Growth: Unable to compare CAPR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CAPR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Return on Equity

High ROE: CAPR has a negative Return on Equity (-242.96%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies